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Abstract  ʹͻ
Disorders of sex development (DSD) are congenital conditions where chromosomal, ͵Ͳ
gonad or genital development is atypical. In a significant proportion of 46,XY DSD ͵ͳ
cases it is not possible to identify a causative mutation, making genetic counseling ͵ʹ
difficult and potentially hindering optimal treatment. We present here the analysis of a ͵͵
46,XY DSD patient that presented at birth with ambiguous genitalia. Histological ͵Ͷ
analysis of the surgically-removed gonads showed bilateral undifferentiated gonadal ͵ͷ
tissue and immature testis, both containing malignant germ cells. We screened genomic ͵͸
DNA from this patient for deletions and duplications using an Illumina whole genome ͵͹
SNP microarray. This analysis revealed a heterozygous deletion within the WWOX gene ͵ͺ
on chromosome 16, removing exons 6-8. Analysis of parental DNA showed that the ͵ͻ
deletion was inherited from the mother. cDNA analysis confirmed that the deletion ͶͲ
maintained the reading frame, with exon 5 being spliced directly onto exon 9. This Ͷͳ
deletion is the first description of a germline rearrangement affecting the coding Ͷʹ
sequence of WWOX in humans.  Previously described Wwox knockout mouse models Ͷ͵
showed gonadal abnormalities, supporting a role for WWOX in human gonad ͶͶ
development.  Ͷͷ
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Introduction Ͷͻ
In the early stages of human embryogenesis the developing gonads are bipotent, being ͷͲ
capable of forming either testes or ovaries. In males the expression of the Y ͷͳ
chromosomal SRY gene initiates testis development, while ovarian development in ͷʹ
principle occurs only in the absence of SRY (reviewed in 1). Following the establishment ͷ͵
of sex-specific expression of key regulatory genes in the gonad, gonadal differentiation ͷͶ
results in develoment of the external genitalia. As a result there are two main stages in ͷͷ
gonad formation, and disruption of either can lead to disorders of sex development ͷ͸
(DSD). DSD are surprisingly common, with ambiguous genitalia estimated to occur ͷ͹
with an incidence of 1 in 4500 live births 2.  ͷͺ
A number of genes important in the regulation of sex determination have been ͷͻ
identified, yet in as many as 70% of 46,XY DSD cases no genetic cause has been ͸Ͳ
identified. We have previously demonstrated the power of whole genome copy number ͸ͳ
analysis with high density microarrays to identify causative mutations in DSD 3, 4. Here ͸ʹ
we describe the use of this approach to identify a multi-exon heterozygous deletion in ͸͵
the WWOX gene of a 46,XY DSD patient. ͸Ͷ
 ͸ͷ
Materials and Methods ͸͸
Array hybridization and analysis ͸͹
Genomic DNA was hybridized onto an Illumina 610-Quad microarray at the Australian ͸ͺ
Genome Research Facility (Melbourne, Australia) following manufacturer’s ͸ͻ
instructions.  Data were analyzed using Genome Studio data analysis software ͹Ͳ
(Illumina). ͹ͳ
MLPA analysis ͹ʹ
Deletion screening of the WWOX gene was performed with Multiplex Ligation-͹͵
dependent Probe Amplification (MLPA). Probe design, the MLPA reaction and data ͹Ͷ
analysis were performed as previously described 5.  ͹ͷ
RNA extraction, cDNA generation and breakpoint PCR ͹͸
RNA was extracted from lymphocytes obtained from the index case using standard ͹͹
procedures, with cDNA generated using random hexamers and the Transcriptor High ͹ͺ
Fidelity cDNA synthesis kit (Roche, Mannheim, Germany) according to the ͹ͻ
manufacturer’s instructions. The PCR amplification across the deletion used the ͺͲ
following primers; F – 5’ CGAAACCGCCAAGTCTTTT 3’, R – 5’ ͺͳ
CGTCTCTTCGCTCTGAGCTT 3’, and was run under the following conditions:  ͺʹ
1 cycle: 60 seconds 95°C; 35 cycles: 30 seconds 95°C; 30 seconds 58°C; 60 seconds ͺ͵
72°C; 1 cycle: 20 min 72°C.  ͺͶ
DNA Sequencing ͺͷ
Sanger sequencing was conducted at the Department of Pathology, University of ͺ͸
Melbourne. ͺ͹
Histological and Immunohistochemical Analysis ͺͺ
Research on human tissue samples was performed according to the Code for Proper ͺͻ
Secondary Use of Human Tissue in The Netherlands, as developed by the Dutch ͻͲ
Federation of Medical Scientific Societies (FMWV) version 2002, and approved by an ͻͳ
institutional review board (MEC 02.981). Immunohistochemical detection of formalin-ͻʹ
fixed paraffin-embedded tissue was performed for SOX9 and FOXL2 6, OCT3/4 7, and ͻ͵
KITL 8, as described previously.  ͻͶ
 ͻͷ
Results ͻ͸
Physical examination of the index patient at the age of ten days revealed unfused ͻ͹
labioscrotal folds, impalpable gonads, clitoral hypertrophy 20mm in size, and a perineal ͻͺ
urogenital sinus. Genitography demonstrated the presence of a vagina and ͻͻ
underdeveloped uterus. Chromosomal analysis showed a 46,XY karyotype with no ͳͲͲ
visible aberrations. Sequence analysis of the SRY and NR5A1 genes did not reveal any ͳͲͳ
variants, and MLPA analysis with a commercially available kit (MLPA P185-B1) ͳͲʹ
containing probes targeted at the WNT4, SRY, NR0B1, SOX9 and NR5A1 genes did not ͳͲ͵
show any deletions or duplications. ͳͲͶ
Small dysgenic gonads were present in the abdomen, and pathological analysis ͳͲͷ
following complete removal at two years of age showed that they contained oedematous ͳͲ͸
infantile testicular parenchyma (Figure 1). The epididymis was completely separated ͳͲ͹
from the rete testis on both sides, and tubair epithelium was identified at the left side. ͳͲͺ
The left gonad consisted of centrally located oedematous testicular tissue, positive for ͳͲͻ
immunohistochemical detection of SOX9 (indicative for Sertoli cells) and negative for ͳͳͲ
FOXL2 (a granulosa cell marker). A gradual transition towards undifferentiated gonadal ͳͳͳ
tissue, containing both SOX9 and FOXL2 positive cells at the upper and lower poles ͳͳʹ
were identified. Undifferentiated gonadal tissue is a gonadal pattern found specifically ͳͳ͵
in patients with gonadal dysgenesis and is typically characterized by the combined ͳͳͶ
expression of FOXL2 and SOX9 (usually with a preponderance of FOXL2), suggesting ͳͳͷ
limited differentiation of the supportive cell lineage into pre-granulosa and pre-Sertoli ͳͳ͸
cells9.  Immature OCT3/4-positive germ cells were also found, either dispersed in ͳͳ͹
ovarian-like stroma or organized together with Sertoli/granulosa cells in cord-like ͳͳͺ
structures, reminiscent of sex cords. These structures have been recognized as the ͳͳͻ
precursor lesion for gonadoblastoma10.  ͳʹͲ
In spite of the presence of ovarian-like stroma, no ovarian follicles were present, and ͳʹͳ
therefore the histology did not allow the diagnosis of ovarian differentiation. The right ͳʹʹ
gonad displayed a similar morphology, with predominant, SOX9 positive testicular ͳʹ͵
differentiation, except for the upper pole, where a large area of FOXL2 positive ͳʹͶ
undifferentiated gonadal tissue was seen, also containing scarce SOX9 positive cells. ͳʹͷ
Based on morphological criteria and immunohistochemical analysis for OCT3/4 and ͳʹ͸
TSPY (showing co-expression of both markers), presence of pre-malignant germ cells ͳʹ͹
was diagnosed. The co-expression is assumed to identify the earliest pathogenetic ͳʹͺ
changes in the genesis of malignant germ cell tumors. That the germ cells are indeed ͳʹͻ
transformed was confirmed by staining for KITL. A limited hormonal work-up was ͳ͵Ͳ
carried out in the neonatal period, with normal values for ACTH, cortisol and 17 ͳ͵ͳ
hydroxy progesterone. At 28 weeks, serum values were obtained for LH and FSH and ͳ͵ʹ
were 1.0 and 5.2 U/l respectively. Although FSH levels were not measured prior to this, ͳ͵͵
the relatively high value at this age suggests a higher value (in the range of gonadal ͳ͵Ͷ
dysgenesis) during full mini-puberty. A HCG test performed at 18 months shows a ͳ͵ͷ
moderate rise of testosterone (testosterone 231 ng/dl after HCG, 500U, 2x/week for 3 ͳ͵͸
weeks). ͳ͵͹
 ͳ͵ͺ
Microarray analysis did not reveal deletions or duplications covering any genes already ͳ͵ͻ
known to be involved in DSD. The most promising candidate rearrangement was a 767 ͳͶͲ
kb deletion on chr 16 (chr16:76956767-77723905; hg18) (Figure 2a). This deletion was ͳͶͳ
located within the WWOX gene, and removed exons 6-8. MLPA probes for each of the ͳͶʹ
nine WWOX exons were designed, and MLPA analysis confirmed that the deletion was ͳͶ͵
restricted to these three exons (data not shown). The deletion is predicted to generate an ͳͶͶ
alternative, in-frame mRNA product, with exon 5 being spliced directly onto exon 9. ͳͶͷ
This alternative transcript was verified by sequencing cDNA derived from matched ͳͶ͸
lymphocytes (Figure 2b).  ͳͶ͹
MLPA analysis of parental DNA samples revealed that the deletion was maternally ͳͶͺ
inherited, with no evidence of mosaicism 11. The clinical history of the mother included ͳͶͻ
a relatively late menarche (16 yrs) with irregular menstruation up to the first pregnancy. ͳͷͲ
Prior to this pregnancy she had received hormonal stimulation, but this was stopped ͳͷͳ
prior to conception. Four subsequent pregnancies occurred naturally. DNA analysis of ͳͷʹ
the children (two brothers and two sisters, all unaffected) showed that none had ͳͷ͵
inherited the deletion. Analysis of the WWOX gene in the index case did not show any ͳͷͶ
sequence variants.  ͳͷͷ
 ͳͷ͸
Discussion ͳͷ͹
We report here the first germline rearrangement affecting the coding sequence of the ͳͷͺ
WWOX gene. WWOX consists of 9 exons, and is >1 Mb in size. It is located on the long ͳͷͻ
arm of chromosome 16 in a known fragile site frequently rearranged in a wide range of ͳ͸Ͳ
cancers 12, and is a suspected tumour suppressor gene 13.  ͳ͸ͳ
WWOX encodes a 414 aa, 46 kDa protein 14. At the amino terminus there are two WW ͳ͸ʹ
domains, with a short chain oxidoreductase (SDR) domain within the central portion of ͳ͸͵
the protein 15. The WW domains are believed to be involved in protein-protein ͳ͸Ͷ
interactions, including a number of transcription factors 16, 17. The SDR region is ͳ͸ͷ
thought to play a role in steroid metabolism 18, with the exon 6-8 deletion identified in ͳ͸͸
this study maintaining the reading frame but effectively ablating the SDR domain from ͳ͸͹
the predicted protein (Figure 2c).  ͳ͸ͺ
Two different Wwox knock-out mouse models have show gonadal abnormalities, ͳ͸ͻ
including defects of Leydig cell function in the testis 18, 19. There are various possible ͳ͹Ͳ
mechanisms for WWOX-mediated testicular dysfunction. WWOX expression inhibits ͳ͹ͳ
the Wnt/β-catenin pathway in a dose dependent manner, although this inhibition is ͳ͹ʹ
reduced if the SDR domain is removed 20. The Wnt/β-catenin pathway is involved in ͳ͹͵
normal ovarian development, and increased Wnt/β-catenin activity in the developing ͳ͹Ͷ
gonad through compromised WWOX activity may interfere with normal testis ͳ͹ͷ
development. Indeed, expression of a stabilized form of β-catenin in the somatic cells of ͳ͹͸
XY mice leads to male to female sex reversal 21. ͳ͹͹
WWOX expression is high in endocrine tissues such as pituitary, testis and ovary 22, and ͳ͹ͺ
it may have a role in gonadotrophin or sex-steroid biosynthesis. It has been suggested ͳ͹ͻ
that a truncated WWOX protein consisting of both WW domains but without a ͳͺͲ
functional SDR domain may act as a competitor of the full-length protein. The truncated ͳͺͳ
WWOX could bind to WWOX-interacting proteins via the WW domains, but would not ͳͺʹ
have any SDR activity 20. ͳͺ͵
Although the mother of the index case carried the same deletion there was a milder ͳͺͶ
gonadal phenotype, with late menarche. An increase in activity of the Wnt/β-catenin ͳͺͷ
pathway due to reduced WWOX activity would not necessarily be expected to have an ͳͺ͸
effect on ovarian development, as this pathway is already active during this process. ͳͺ͹
There may however be a disturbed ovarian function due to impaired steroidogenesis, as ͳͺͺ
was observed in one of the mouse models 18.  ͳͺͻ
In conclusion, we have identified a multi-exon deletion in WWOX in a 46,XY DSD ͳͻͲ
patient with ambiguous genitalia. This finding is the first germline rearrangement ͳͻͳ
affecting WWOX coding sequence described in humans, and implicates WWOX in ͳͻʹ
normal gonadal development. ͳͻ͵
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Figure 1. Representative histological and immunohistochemical findings for the left ʹͲͶ
gonad: A) total overview of the gonad histology (H & E); B) higher magnification (2.5x ʹͲͷ
magnification, indicated by square in A); immunohistochemical detection of C) SOX9, ʹͲ͸
positive in the Sertoli cells; D) FOXL2, positive in the granulosa cells; E) OCT3/4; F) ʹͲ͹
TSPY; G) KITL, all positive in the transformed germ cells. All immunohistochemical ʹͲͺ
images are at the magnification of 100x, except G, being 50x.    ʹͲͻ
 ʹͳͲ
Figure 2. Molecular analysis of DNA from the 46,XY DSD patient. (A). The deletion ʹͳͳ
identified by microarray analysis, removing 767 kb of genomic DNA on chromosome ʹͳʹ
16. Data are plotted along the chromosome, with each point representing the copy ʹͳ͵
number estimate of an individual probe. The breakpoints of the deletion are shown by ʹͳͶ
the broken vertical lines. (B) PCR analysis of the deletion. cDNA was derived from ʹͳͷ
lymphocytes of the index patient, and primers were designed to amplify a PCR product ʹͳ͸
across the predicted breakpoint. Sequence analysis shows that exon 5 is spliced directly ʹͳ͹
onto exon 9. (C) Effect of the deletion on the WWOX protein. The full length WWOX ʹͳͺ
protein has two WW domains at the N-terminal, and a short chain oxidoreductase ʹͳͻ
(SDR) domain at the C-terminal. A deletion of exons 6-8 is predicted to result in an in-ʹʹͲ
frame but shortened product, with the SDR domain largely missing. ʹʹͳ
 ʹʹʹ
 ʹʹ͵
 ʹʹͶ
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